RCT 2100
Alternative Names: Cystic fibrosis mRNA therapeutic - ReCode Therapeutics; RCT-2100Latest Information Update: 03 Oct 2024
Price :
$50 *
At a glance
- Originator ReCode Therapeutics
- Class Antifibrotics; RNA
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cystic fibrosis
Most Recent Events
- 27 Sep 2024 Pharmacodynamics data from a preclinical trial in Cystic fibrosis released by ReCode Therapeutics
- 21 Feb 2024 ReCode announces intention to submit IND to US FDA for Cystic fibrosis for a phase I trial of RCT 2100 in the first half of 2024
- 01 Feb 2024 Phase-I clinical trials in Cystic fibrosis in New Zealand (Inhalation) (NCT06237335)